Tri Ri Asset Management Corp Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Tri Ri Asset Management Corp purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 21,448 shares of the biotechnology company's stock, valued at approximately $7,686,000. United Therapeutics makes up approximately 3.9% of Tri Ri Asset Management Corp's investment portfolio, making the stock its 9th biggest position.

A number of other institutional investors have also added to or reduced their stakes in UTHR. ClariVest Asset Management LLC increased its holdings in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $30,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter worth $33,000. Finally, Brooklyn Investment Group bought a new stake in United Therapeutics during the third quarter valued at about $33,000. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on UTHR shares. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 20th. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

Insider Transactions at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $1,034,510.88. This represents a 85.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 119,340 shares of company stock worth $44,765,530. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Performance

United Therapeutics stock traded up $0.20 during mid-day trading on Friday, reaching $361.81. 286,098 shares of the company were exchanged, compared to its average volume of 447,705. The firm has a market cap of $16.15 billion, a P/E ratio of 15.88, a PEG ratio of 1.05 and a beta of 0.54. The business has a fifty day moving average of $369.82 and a 200 day moving average of $341.06. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.38 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.